<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39062904</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>14</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Immune Stimulation with Imiquimod to Best Face SARS-CoV-2 Infection and Prevent Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7661</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25147661</ELocationID><Abstract><AbstractText>Through widespread immunization against SARS-CoV-2 <i>prior</i> to or <i>post</i>-infection, a substantial segment of the global population has acquired both humoral and cellular immunity, and there has been a notable reduction in the incidence of severe and fatal cases linked to this virus and accelerated recovery times for those infected. Nonetheless, a significant demographic, comprising around 20% to 30% of the adult population, remains unimmunized due to diverse factors. Furthermore, alongside those recovered from the infection, there is a subset of the population experiencing persistent symptoms referred to as Long COVID. This condition is more prevalent among individuals with underlying health conditions and immune system impairments. Some Long COVID pathologies stem from direct damage inflicted by the viral infection, whereas others arise from inadequate immune system control over the infection or suboptimal immunoregulation. There are differences in the serum cytokines and miRNA profiles between infected individuals who develop severe COVID-19 or Long COVID and those who control adequately the infection. This review delves into the advantages and constraints associated with employing imiquimod in human subjects to enhance the immune response during SARS-CoV-2 immunization. Restoration of the immune system can modify it towards a profile of non-susceptibility to SARS-CoV-2. An adequate immune system has the potential to curb viral propagation, mitigate symptoms, and ameliorate the severe consequences of the infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pacheco-Garc&#xed;a</LastName><ForeName>Ursino</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cardio-Renal Pathophysiology, Instituto Nacional de Cardiolog&#xed;a "Ignacio Ch&#xe1;vez", Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varela-L&#xf3;pez</LastName><ForeName>Elvira</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Translational Medicine, Instituto Nacional de Cardiolog&#xed;a "Ignacio Ch&#xe1;vez", Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seraf&#xed;n-L&#xf3;pez</LastName><ForeName>Jeanet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology, Escuela Nacional de Ciencias Biol&#xf3;gicas (ENCB), Instituto Polit&#xe9;cnico Nacional (IPN), Mexico City 11340, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Not applied</GrantID><Agency>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez</Agency><Country/></Grant><Grant><GrantID>Not Applied</GrantID><Agency>Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P1QW714R7M</RegistryNumber><NameOfSubstance UI="D000077271">Imiquimod</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077271" MajorTopicYN="Y">Imiquimod</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 immunization</Keyword><Keyword MajorTopicYN="N">imiquimod immunostimulation</Keyword></KeywordList><CoiStatement>The authors have no financial involvement in any organization or entity with a financial interest in or financial conflict with the subject matter discussed in the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>28</Day><Hour>14</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39062904</ArticleId><ArticleId IdType="pmc">PMC11277483</ArticleId><ArticleId IdType="doi">10.3390/ijms25147661</ArticleId><ArticleId IdType="pii">ijms25147661</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020;130:2620&#x2013;2629. doi: 10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta D., Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157&#x2013;160. doi: 10.23750/abm.v91i1.9397.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i1.9397</ArticleId><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . WHO COVID-19 Dashboard. WHO; Geneva, Switzerland: 2020.  [(accessed on 2 July 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>WHO.  [(accessed on 20 March 2024)].  Available online:  https://covid19.who.int/?mapFilter=vaccinations.</Citation></Reference><Reference><Citation>Sumirtanurdin R., Barliana M.I. Coronavirus disease 2019 vaccine development: An overview. Viral Immunol. 2021;34:134&#x2013;144. doi: 10.1089/vim.2020.0119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2020.0119</ArticleId><ArticleId IdType="pubmed">32985963</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507&#x2013;513. doi: 10.1016/S0140-6736(20)30211-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>DeSalvo K., Hughes B., Bassett M., Benjamin G., Fraser M., Galea S., Gracia J.N., Howard J. Public Health COVID-19 Impact Assessment: Lessons Learned and Compelling Needs. NAM Perspect. 2021;2021:202104c. doi: 10.31478/202104c.</Citation><ArticleIdList><ArticleId IdType="doi">10.31478/202104c</ArticleId><ArticleId IdType="pmc">PMC8406505</ArticleId><ArticleId IdType="pubmed">34532688</ArticleId></ArticleIdList></Reference><Reference><Citation>Linton P.J., Dorshkind K. Age-related changes in lymphocyte development and function. Nat. Immunol. 2004;5:133&#x2013;139. doi: 10.1038/ni1033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1033</ArticleId><ArticleId IdType="pubmed">14749784</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Yao D., Tan J., He Z., Yu Z., Chen J., Luo G., Wang C., Zhou F., Zha X., et al. Memory T cells skew toward terminal differentiation in the CD8+T cell population in patients with acute myeloid leukemia. J. Hematol. Oncol. 2018;11:93. doi: 10.1186/s13045-018-0636-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-018-0636-y</ArticleId><ArticleId IdType="pmc">PMC6038290</ArticleId><ArticleId IdType="pubmed">29986734</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Yao D., Zeng X., Kasakovski D., Zhang Y., Chen S., Zha X., Li Y., Xu L. Age related human T cell subset evolution and senescence. Immun. Ageing. 2019;16:24. doi: 10.1186/s12979-019-0165-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-019-0165-8</ArticleId><ArticleId IdType="pmc">PMC6739976</ArticleId><ArticleId IdType="pubmed">31528179</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Xu L., Chen C., Zhang Y., Zeng C., Jin Z., Chen S., Li B., Zha X., Yin Z., et al. Age-Related Immune Profileof the T Cell Receptor Repertoire, Thymic Recent Output Function, and miRNAs. BioMed Res. Int. 2020;2020:5910823. doi: 10.1155/2020/5910823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5910823</ArticleId><ArticleId IdType="pmc">PMC7732372</ArticleId><ArticleId IdType="pubmed">33344643</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridharan A., Esposo M., Kaushal K., Tay J., Osann K., Agrawal S., Gupta S., Agrawal A. Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity. Age. 2011;33:363&#x2013;376. doi: 10.1007/s11357-010-9191-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-010-9191-3</ArticleId><ArticleId IdType="pmc">PMC3168606</ArticleId><ArticleId IdType="pubmed">20953722</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbe K., Bratke K., Wagner S., Virchow J.C., Lommatzsch M. Plasmacytoid dendritic cells and their toll-like receptor 9 expression selectively decrease with age. Hum. Immunol. 2012;73:493&#x2013;497. doi: 10.1016/j.humimm.2012.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2012.02.007</ArticleId><ArticleId IdType="pubmed">22386694</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash S., Agrawal S., Cao J.N., Gupta S., Agrawal A. Impaired secretion of interferons by dendritic cells from aged subjects to influenza: Role of histone modifications. Age. 2013;35:1785&#x2013;1797. doi: 10.1007/s11357-012-9477-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-012-9477-8</ArticleId><ArticleId IdType="pmc">PMC3776111</ArticleId><ArticleId IdType="pubmed">23007963</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S., Tran M.T., Jennings T.S.K., Soliman M.M.H., Heo S., Sasson B., Rahmatpanah F., Agrawal A. Changes in the innate immune response to SARS-CoV-2 with advancing age in humans. Immun. Ageing. 2024;21:21. doi: 10.1186/s12979-024-00426-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-024-00426-3</ArticleId><ArticleId IdType="pmc">PMC10956333</ArticleId><ArticleId IdType="pubmed">38515147</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesta M.C., Zippoli M., Marsiglia C., Gavioli E.M., Mantelli F., Allegretti M., Balk R.A. The role of Interleukin-8 in lung inflammation and Injury: Implications for the management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome. Front. Pharmacol. 2022;12:808797. doi: 10.3389/fphar.2021.808797.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.808797</ArticleId><ArticleId IdType="pmc">PMC8790527</ArticleId><ArticleId IdType="pubmed">35095519</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Li J., Gao M., Fan H., Wang Y., Xu X., Chen C., Liu J., Kim J., Aliyari R., et al. Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 patients. Front. Immunol. 2021;11:602395. doi: 10.3389/fimmu.2020.602395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.602395</ArticleId><ArticleId IdType="pmc">PMC7820901</ArticleId><ArticleId IdType="pubmed">33488599</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibot S., Lafon T., Jacquin L., Lefevre B., Kimmoun A., Guillaumot A., Losser M.-R., Douplat M., Argaud L., De Ciancio G., et al. Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients. Intensiv. Care Med. Exp. 2023;11:51. doi: 10.1186/s40635-023-00532-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40635-023-00532-4</ArticleId><ArticleId IdType="pmc">PMC10423708</ArticleId><ArticleId IdType="pubmed">37574520</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira Y.L.M., Resende A.d.S., Martins-Filho P.R., de Moura T.R. Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: A systematic review and meta-analysis of clinical studies. Inflammopharmacology. 2022;30:1037&#x2013;1045. doi: 10.1007/s10787-022-00972-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00972-6</ArticleId><ArticleId IdType="pmc">PMC8959072</ArticleId><ArticleId IdType="pubmed">35347523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammock B.D., Wang W., Gilligan M.M., Panigrahy D. Eicosanoids: The overlooked storm in Coronavirus Disease 2019 (COVID-19)? Am. J. Pathol. 2020;190:1782&#x2013;1788. doi: 10.1016/j.ajpath.2020.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.06.010</ArticleId><ArticleId IdType="pmc">PMC7340586</ArticleId><ArticleId IdType="pubmed">32650004</ArticleId></ArticleIdList></Reference><Reference><Citation>Archambault A.-S., Zaid Y., Rakotoarivelo V., Turcotte C., Dor&#xe9; &#xc9;., Dubuc I., Martin C., Flamand O., Amar Y., Cheikh A., et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. FASEB J. 2021;35:e21666. doi: 10.1096/fj.202100540R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202100540R</ArticleId><ArticleId IdType="pmc">PMC8206770</ArticleId><ArticleId IdType="pubmed">34033145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray D., Yung R. Immune senescence, epigenetics and autoimmunity. Clin. Immunol. 2018;196:59&#x2013;63. doi: 10.1016/j.clim.2018.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2018.04.002</ArticleId><ArticleId IdType="pmc">PMC6548177</ArticleId><ArticleId IdType="pubmed">29654845</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xfc;l&#xf6;p T., Dupuis G., Witkowski J.M., Larbi A. The Role of Immunosenescence in the Development of Age-Related Diseases. Rev. Investig. Clin. 2016;68:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">27103044</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimi G., Sohouli M.H., Ghorbani A., Shakery A., Zand H. The interplay between obesity, immunosenescence, and insulin resistance. Immun. Ageing. 2024;21:13. doi: 10.1186/s12979-024-00414-7. Erratum in Immun. Ageing 2024, 21, 31. https://doi.org/10.1186/s12979-024-00438-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-024-00414-7</ArticleId><ArticleId IdType="pmc">PMC10840211</ArticleId><ArticleId IdType="pubmed">38317257</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F., Zheng K.I., Wang X.-B., Sun Q.-F., Pan K.-H., Wang T.-Y., Chen Y.-P., Targher G., Byrne C.D., George J., et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020;43:e724. doi: 10.2337/dc20-0682.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-0682</ArticleId><ArticleId IdType="pubmed">32409499</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruglikov I.L., Scherer P.E. The role of adipocytes and adipocyte like cells in the severity of COVID-19 infections. Obesity. 2020;28:1187&#x2013;1190. doi: 10.1002/oby.22856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.22856</ArticleId><ArticleId IdType="pmc">PMC7267593</ArticleId><ArticleId IdType="pubmed">32339391</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E., Rawlik K., Bretherick A.D., Qi T., Wu Y., Nassiri I., McConkey G.A., Zechner M., Klaric L., Griffiths F., et al. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature. 2023;617:764&#x2013;768. doi: 10.1038/s41586-023-06034-3. Erratum in Nature 2023, 619, E61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06034-3</ArticleId><ArticleId IdType="pmc">PMC10208981</ArticleId><ArticleId IdType="pubmed">37198478</ArticleId></ArticleIdList></Reference><Reference><Citation>Edahiro R., Shirai Y., Takeshima Y., Sakakibara S., Yamaguchi Y., Murakami T., Morita T., Kato Y., Liu Y.-C., Motooka D., et al. Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity. Nat. Genet. 2023;55:753&#x2013;767. doi: 10.1038/s41588-023-01375-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-023-01375-1</ArticleId><ArticleId IdType="pmc">PMC10181941</ArticleId><ArticleId IdType="pubmed">37095364</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadras O., Afsahi A.M., Pashaei Z., Mojdeganlou H., Karimi A., Habibi P., Barzegary A., Fakhfouri A., Mirzapour P., Janfaza N., et al. The relationship between COVID-19 viral load and disease severity: A systematic review. Immunity Inflamm. Dis. 2021;10:e580. doi: 10.1002/iid3.580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.580</ArticleId><ArticleId IdType="pmc">PMC8926507</ArticleId><ArticleId IdType="pubmed">34904379</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M., Shen W., Rowan N.R., Kulaga H., Hillel A., Ramanathan M., Lane A.P. Elevated ACE-2 expression in the olfactory neuroepithelium: Implications for anosmia and upper respiratory SARS-CoV-2 entry and replication. Eur. Respir. J. 2020;56:2001948. doi: 10.1183/13993003.01948-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01948-2020</ArticleId><ArticleId IdType="pmc">PMC7439429</ArticleId><ArticleId IdType="pubmed">32817004</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020;71:762&#x2013;768. doi: 10.1093/cid/ciaa248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L., Wang Q., Zhang D., Ding J., Huang Q., Tang Y.-Q., Wang Q., Miao H. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal Transduct. Target. Ther. 2020;5:33. doi: 10.1038/s41392-020-0148-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-0148-4</ArticleId><ArticleId IdType="pmc">PMC7100419</ArticleId><ArticleId IdType="pubmed">32296069</ArticleId></ArticleIdList></Reference><Reference><Citation>Azkur A.K., Akdis M., Azkur D., Sokolowska M., van de Veen W., Br&#xfc;ggen M., O&#x2019;mahony L., Gao Y., Nadeau K., Akdis C.A. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes inCOVID-19. Allergy. 2020;75:1564&#x2013;1581. doi: 10.1111/all.14364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14364</ArticleId><ArticleId IdType="pmc">PMC7272948</ArticleId><ArticleId IdType="pubmed">32396996</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva M.J.A., Ribeiro L.R., Gouveia M.I.M., Marcelino B.d.R., dos Santos C.S., Lima K.V.B., Lima L.N.G.C. Hyperinflammatory Response in COVID-19: A Systematic Review. Viruses. 2023;15:553. doi: 10.3390/v15020553.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020553</ArticleId><ArticleId IdType="pmc">PMC9962879</ArticleId><ArticleId IdType="pubmed">36851766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangoni A.A., Zinellu A. Systemic inflammation index, disease severity, and mortality in patients with COVID-19: A systematic review and meta-analysis. Front. Immunol. 2023;14:1212998. doi: 10.3389/fimmu.2023.1212998.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1212998</ArticleId><ArticleId IdType="pmc">PMC10320859</ArticleId><ArticleId IdType="pubmed">37415980</ArticleId></ArticleIdList></Reference><Reference><Citation>Morawska L., Milton D.K. It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19) Clin. Infect. Dis. 2020;71:2311&#x2013;2313. doi: 10.1093/cid/ciaa939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa939</ArticleId><ArticleId IdType="pmc">PMC7454469</ArticleId><ArticleId IdType="pubmed">32628269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324:782&#x2013;793. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Y&#xfc;ce M., Filiztekin E., &#xd6;zkaya K.G. COVID-19 diagnosis&#x2014;A review of current methods. Biosens. Bioelectron. 2020;172:112752. doi: 10.1016/j.bios.2020.112752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bios.2020.112752</ArticleId><ArticleId IdType="pmc">PMC7584564</ArticleId><ArticleId IdType="pubmed">33126180</ArticleId></ArticleIdList></Reference><Reference><Citation>Costanza G., Paba P., Ciotti M., Ombres D., Di Carlo S., Marcuccilli F., Bertoli A., Di Traglia L., Mozzani M., Piredda L., et al. Infection Rate of Respiratory Viruses in the Pandemic SARS-CoV-2 Period Considering Symptomatic Patients Two Years of Ongoing Observations. Biomolecules. 2022;12:987. doi: 10.3390/biom12070987.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12070987</ArticleId><ArticleId IdType="pmc">PMC9313449</ArticleId><ArticleId IdType="pubmed">35883543</ArticleId></ArticleIdList></Reference><Reference><Citation>Komurcuoglu B., Susam S., Batum &#xd6;., Turk M.A., Salik B., Karadeniz G., Senol G. Correlation between chest CT severity scores and clinical and biochemical parameters of COVID-19 pneumonia. Clin. Respir. J. 2022;16:497&#x2013;503. doi: 10.1111/crj.13515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/crj.13515</ArticleId><ArticleId IdType="pmc">PMC9329017</ArticleId><ArticleId IdType="pubmed">35750636</ArticleId></ArticleIdList></Reference><Reference><Citation>Quirit A.M., Sorreda J., Pinera R., Tobias K.K. Serum ferritin level as a prognostic marker of 30 days in hospital mortalityof coronavirus disease 2019 (COVID-19) pneumonia at World City Medical Center: A retrospective observational cohort, single center study. Int. J. Coronaviruses. 2021;3:20&#x2013;29. doi: 10.14302/issn.2692-1537.ijcv-21-4025.</Citation><ArticleIdList><ArticleId IdType="doi">10.14302/issn.2692-1537.ijcv-21-4025</ArticleId></ArticleIdList></Reference><Reference><Citation>Solanich X., Vargas-Parra G., van der Made C.I., Simons A., Schuurs-Hoeijmakers J., Antol&#xed; A., del Valle J., Rocamora-Blanch G., Seti&#xe9;n F., Esteller M., et al. Genetic Screening for TLR7 Variants in Young and Previously Healthy Men with Severe COVID-19. Front. Immunol. 2021;12:719115. doi: 10.3389/fimmu.2021.719115.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.719115</ArticleId><ArticleId IdType="pmc">PMC8343010</ArticleId><ArticleId IdType="pubmed">34367187</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastassopoulou C., Gkizarioti Z., Patrinos G.P., Tsakris A. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Hum. Genom. 2020;14:40. doi: 10.1186/s40246-020-00290-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40246-020-00290-4</ArticleId><ArticleId IdType="pmc">PMC7578581</ArticleId><ArticleId IdType="pubmed">33092637</ArticleId></ArticleIdList></Reference><Reference><Citation>I&#x161;a P., Taboada B., Garc&#xed;a-L&#xf3;pez R., Boukadida C., Ram&#xed;rez-Gonz&#xe1;lez J.E., V&#xe1;zquez-P&#xe9;rez J.A., Hern&#xe1;ndez-Ter&#xe1;n A., Romero-Espinoza J., Mu&#xf1;oz-Medina J.E., Grajales-Mu&#xf1;iz C., et al. Metagenomic analysis reveals differences in the co-occurrence and abundance of viral species in SARS-CoV-2 patients with different severity of disease. BMC Infect. Dis. 2022;22:792. doi: 10.1186/s12879-022-07783-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07783-8</ArticleId><ArticleId IdType="pmc">PMC9580447</ArticleId><ArticleId IdType="pubmed">36261802</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel C.E. Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease. J. Biol. Chem. 2023;299:104960. doi: 10.1016/j.jbc.2023.104960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.104960</ArticleId><ArticleId IdType="pmc">PMC10290182</ArticleId><ArticleId IdType="pubmed">37364688</ArticleId></ArticleIdList></Reference><Reference><Citation>Routen A., Khunti K. Long-term outcomes in hospitalised COVID-19 survivors and future research priorities. Lancet Respir. Med. 2024;12:7&#x2013;8. doi: 10.1016/S2213-2600(23)00410-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00410-1</ArticleId><ArticleId IdType="pubmed">38000377</ArticleId></ArticleIdList></Reference><Reference><Citation>Terzic C.M., Medina-Inojosa B.J. Cardiovascular complications of COVID-19. Phys. Med. Rehabil. Clin. North Am. 2023;34:551&#x2013;561. doi: 10.1016/j.pmr.2023.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmr.2023.03.003</ArticleId><ArticleId IdType="pmc">PMC10063539</ArticleId><ArticleId IdType="pubmed">37419531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G.Q., Gu Y., Wang C., Wang F., Hsu A.C.-Y. A Game of Infection&#x2014;Song of Respiratory Viruses and Interferons. Front. Cell. Infect. Microbiol. 2022;12:937460. doi: 10.3389/fcimb.2022.937460.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.937460</ArticleId><ArticleId IdType="pmc">PMC9277140</ArticleId><ArticleId IdType="pubmed">35846766</ArticleId></ArticleIdList></Reference><Reference><Citation>Copaescu A., Smibert O., Gibson A., Phillips E.J., Trubiano J.A. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J. Allergy Clin. Immunol. 2020;146:518&#x2013;534.e1. doi: 10.1016/j.jaci.2020.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7471766</ArticleId><ArticleId IdType="pubmed">32896310</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannaccone G., Scacciavillani R., Del Buono M.G., Camilli M., Ronco C., Lavie C.J., Abbate A., Crea F., Massetti M., Aspromonte N. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. Cardiorenal Med. 2020;10:277&#x2013;287. doi: 10.1159/000509483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000509483</ArticleId><ArticleId IdType="pmc">PMC7360507</ArticleId><ArticleId IdType="pubmed">32599589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., P&#xe9;r&#xe9; H., Charbit B., Bondet V., Chenevier-Gobeaux C., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718&#x2013;724. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Yu F., Chang W., Zhang Y., Zhang L., Li P. Inflammasomes: A rising star on the horizon of COVID-19 pathophysiology. Front. Immunol. 2023;14:1185233. doi: 10.3389/fimmu.2023.1185233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1185233</ArticleId><ArticleId IdType="pmc">PMC10213254</ArticleId><ArticleId IdType="pubmed">37251383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammi V., Nakanishi T., Jones S.E., Andrews S.J., Karjalainen J., Cort&#xe9;s B., O&#x2019;Brien H.E., Fulton-Howard B.E., Haapaniemi H.H., Schmidt A., et al. Genome-Wide Association Study of Long COVID. medRxiv. 2023;2023:6.</Citation></Reference><Reference><Citation>Ledford H. Gene linked to long COVID found in analysis of thousands of patients. Nature. 2023;619:445. doi: 10.1038/d41586-023-02269-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-02269-2</ArticleId><ArticleId IdType="pubmed">37433943</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannella A., Riccetti S., Sinigaglia A., Piubelli C., Razzaboni E., Di Battista P., Agostini M., Molin E.D., Manganelli R., Gobbi F., et al. Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients. Front. Immunol. 2022;13:968991. doi: 10.3389/fimmu.2022.968991.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.968991</ArticleId><ArticleId IdType="pmc">PMC9403711</ArticleId><ArticleId IdType="pubmed">36032130</ArticleId></ArticleIdList></Reference><Reference><Citation>Saulle I., Garziano M., Cappelletti G., Limanaqi F., Strizzi S., Vanetti C., Caputo S.L., Poliseno M., Santantonio T.A., Clerici M., et al. Salivary miRNA Profiles in COVID-19 Patients with Different Disease Severities. Int. J. Mol. Sci. 2023;24:10992. doi: 10.3390/ijms241310992.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241310992</ArticleId><ArticleId IdType="pmc">PMC10341682</ArticleId><ArticleId IdType="pubmed">37446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayt&#xe1;n-Pacheco N., Ib&#xe1;&#xf1;ez-Salazar A., Oostdam A.S.H.-V., Oropeza-Valdez J.J., Maga&#xf1;a-Aquino M., L&#xf3;pez J.A., Mon&#xe1;rrez-Espino J., L&#xf3;pez-Hern&#xe1;ndez Y. miR-146a, miR-221, and miR-155 areInvolved in Inflammatory Immune Response in Severe COVID-19 Patients. Diagnostics. 2023;13:133. doi: 10.3390/diagnostics13010133.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics13010133</ArticleId><ArticleId IdType="pmc">PMC9818442</ArticleId><ArticleId IdType="pubmed">36611425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovarik J.J., Bileck A., Hagn G., Meier-Menches S.M., Frey T., Kaempf A., Hollenstein M., Shoumariyeh T., Skos L., Reiter B., et al. A multi-omics based anti-inflammatory immune signature characterizes Long COVID-19 syndrome. iScience. 2022;26:105717. doi: 10.1016/j.isci.2022.105717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105717</ArticleId><ArticleId IdType="pmc">PMC9719844</ArticleId><ArticleId IdType="pubmed">36507225</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Blish C.A., Sallusto F., Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122&#x2013;1127. doi: 10.1126/science.abm8108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann D.M., Whettlock E.M., Liu S., Arachchillage D.J., Boyton R.J. The immunology of long COVID. Nat. Rev. Immunol. 2023;23:618&#x2013;634. doi: 10.1038/s41577-023-00904-7. Erratum in Nat. Rev. Immunol. 2023, 23, 697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosichini M., Bordoni V., Silvestris D.A., Mariotti D., Matusali G., Cardinale A., Zambruno G., Condorelli A.G., Flamini S., Genah S., et al. SARS-CoV-2 infection of thymus induces loss of function thatcorrelates with disease severity. J. Allergy Clin. Immunol. 2023;151:911&#x2013;921. doi: 10.1016/j.jaci.2023.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2023.01.022</ArticleId><ArticleId IdType="pmc">PMC9907790</ArticleId><ArticleId IdType="pubmed">36758836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y.-B., Zeng N., Yuan K., Tian S.-S., Yang Y.-B., Gao N., Chen X., Zhang A.-Y., Kondratiuk A.L., Shi P.-P., et al. Prevalence and risk factor for long COVID in children and adolescents: A meta-analysis and systematic review. J. Infect. Public Health. 2023;16:660&#x2013;672. doi: 10.1016/j.jiph.2023.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2023.03.005</ArticleId><ArticleId IdType="pmc">PMC9990879</ArticleId><ArticleId IdType="pubmed">36931142</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco J.V.A., Garegnani L.I., Metzendorf M.-I., Heldt K., Mumm R., Scheidt-Nave C. Post-covid-19 conditions inadults: Systematic review and meta-analysis of health outcomes in controlled studies. BMJ Med. 2024;3:e000723. doi: 10.1136/bmjmed-2023-000723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2023-000723</ArticleId><ArticleId IdType="pmc">PMC10826558</ArticleId><ArticleId IdType="pubmed">38293681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji P., Zhu J., Zhong Z., Li H., Pang J., Li B., Zhang J. Association of elevated inflammatory markers and severe COVID-19: A metaanalysis. Medicine. 2020;99:e23315. doi: 10.1097/MD.0000000000023315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023315</ArticleId><ArticleId IdType="pmc">PMC7676531</ArticleId><ArticleId IdType="pubmed">33217868</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: A prospective cohort study. Intensive Care Med. 2021;47:60&#x2013;73. doi: 10.1007/s00134-020-06294-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06294-x</ArticleId><ArticleId IdType="pmc">PMC7674575</ArticleId><ArticleId IdType="pubmed">33211135</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020;180:934&#x2013;943. doi: 10.1001/jamainternmed.2020.0994. Erratum in JAMA Intern. Med. 2020, 180, 1031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H.S., Choi J.W. Association between COVID-19 and incidence of cardiovascular disease and all-cause mortality among patients with diabetes. Front. Endocrinol. 2023;14:1230176. doi: 10.3389/fendo.2023.1230176.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1230176</ArticleId><ArticleId IdType="pmc">PMC10414181</ArticleId><ArticleId IdType="pubmed">37576978</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Jiang M., Chen X., Montaner L.J. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J. Leukoc. Biol. 2020;108:17&#x2013;41. doi: 10.1002/JLB.3COVR0520-272R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3COVR0520-272R</ArticleId><ArticleId IdType="pmc">PMC7323250</ArticleId><ArticleId IdType="pubmed">32534467</ArticleId></ArticleIdList></Reference><Reference><Citation>Longmore D.K., Miller J.E., Bekkering S., Saner C., Mifsud E., Zhu Y., Saffery R., Nichol A., Colditz G., Short K.R., et al. Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis. Diabetes Care. 2021;44:1281&#x2013;1290. doi: 10.2337/dc20-2676.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-2676</ArticleId><ArticleId IdType="pmc">PMC8247499</ArticleId><ArticleId IdType="pubmed">33858854</ArticleId></ArticleIdList></Reference><Reference><Citation>Zadeh F.H., Wilson D.R., Agrawal D.K. Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies. Arch. Microbiol. Immunol. 2023;7:36&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10310313</ArticleId><ArticleId IdType="pubmed">37388279</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2. Erratum in Nat. Rev. Microbiol. 2023, 21, 408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho C.-Y., Lee A. Cultivating a Healthy Living Environment for Adolescents in the Post-COVID Era in Hong Kong: Exploring Youth Health Needs. Int. J. Environ. Res. Public Health. 2022;19:7072. doi: 10.3390/ijerph19127072.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19127072</ArticleId><ArticleId IdType="pmc">PMC9222256</ArticleId><ArticleId IdType="pubmed">35742326</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;addario M., Adorni R., Steca P., Capelli R., Zanatta F., Fattirolli F., Franzelli C., Giannattasio C., Greco A. Associations between Life style Changes and Adherence to COVID-19 Restrictions in Older Adults with Hypertension. Int. J. Environ. Res. Public Health. 2022;19:7853. doi: 10.3390/ijerph19137853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19137853</ArticleId><ArticleId IdType="pmc">PMC9265744</ArticleId><ArticleId IdType="pubmed">35805511</ArticleId></ArticleIdList></Reference><Reference><Citation>Viner R.M., Mytton O.T., Bonell C., Melendez-Torres G.J., Ward J., Hudson L., Waddington C., Thomas J., Russell S., van der Klis F., et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: A systematic review and meta-analysis. JAMA Pediatr. 2021;175:143&#x2013;156. doi: 10.1001/jamapediatrics.2020.4573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2020.4573</ArticleId><ArticleId IdType="pmc">PMC7519436</ArticleId><ArticleId IdType="pubmed">32975552</ArticleId></ArticleIdList></Reference><Reference><Citation>Nudelman G., Peleg S., Shiloh S. The Association between Healthy Lifestyle Behaviours and Coronavirus Protective Behaviours. Int. J. Behav. Med. 2021;28:779&#x2013;787. doi: 10.1007/s12529-021-09960-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12529-021-09960-6</ArticleId><ArticleId IdType="pmc">PMC7875448</ArticleId><ArticleId IdType="pubmed">33569759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kie&#x142;bowski K., Herian M., Pawlik A. How to Restore Oxidative Balance That Was Disrupted by SARS-CoV-2 Infection. Int. J. Mol. Sci. 2022;23:6377. doi: 10.3390/ijms23126377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23126377</ArticleId><ArticleId IdType="pmc">PMC9223498</ArticleId><ArticleId IdType="pubmed">35742820</ArticleId></ArticleIdList></Reference><Reference><Citation>Roham M., Hejrati A., Nurzadeh M. Association of coronavirus pathogencity with the level of antioxidants and immune system. J. Fam. Med. Prim. Care. 2021;10:609&#x2013;614. doi: 10.4103/jfmpc.jfmpc_1007_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jfmpc.jfmpc_1007_20</ArticleId><ArticleId IdType="pmc">PMC8138403</ArticleId><ArticleId IdType="pubmed">34041049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrityunjaya M., Pavithra V., Neelam R., Janhavi P., Halami P.M., Ravindra P.V. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. Front. Immunol. 2020;11:570122. doi: 10.3389/fimmu.2020.570122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.570122</ArticleId><ArticleId IdType="pmc">PMC7575721</ArticleId><ArticleId IdType="pubmed">33117359</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulas K., Farsalinos K., Zanidis C. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy. Front. Immunol. 2020;11:1373. doi: 10.3389/fimmu.2020.01373.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01373</ArticleId><ArticleId IdType="pmc">PMC7307572</ArticleId><ArticleId IdType="pubmed">32612613</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeto M.D., Maghfour J., Sivesind T.E., Anderson J., Olayinka J.T., Mamo A., Runion T.M., Dellavalle R.P. Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment. Dermatology. 2021;237:847&#x2013;856. doi: 10.1159/000518471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000518471</ArticleId><ArticleId IdType="pmc">PMC8450856</ArticleId><ArticleId IdType="pubmed">34511591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy R. COVID-19 Vaccines for Optimizing Immunity in the Upper Respiratory Tract. Viruses. 2023;15:2203. doi: 10.3390/v15112203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15112203</ArticleId><ArticleId IdType="pmc">PMC10674974</ArticleId><ArticleId IdType="pubmed">38005881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanneganti T.D. Intracellular innate immune receptors: Life inside the cell. Immunol. Rev. 2020;297:5&#x2013;12. doi: 10.1111/imr.12912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12912</ArticleId><ArticleId IdType="pmc">PMC7592123</ArticleId><ArticleId IdType="pubmed">32856334</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno Y., Kimura I., Uriu K., Fukushi M., Irie T., Koyanagi Y., Sauter D., Gifford R.J., Nakagawa S., Sato K. SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant. Cell Rep. 2020;32:108185. doi: 10.1016/j.celrep.2020.108185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108185</ArticleId><ArticleId IdType="pmc">PMC7473339</ArticleId><ArticleId IdType="pubmed">32941788</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.-Y., Liao C.-H., Wang Q., Tan Y.-J., Luo R., Qiu Y., Ge X.-Y. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res. 2020;286:198074. doi: 10.1016/j.virusres.2020.198074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2020.198074</ArticleId><ArticleId IdType="pmc">PMC7309931</ArticleId><ArticleId IdType="pubmed">32589897</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.-C., Uhl S., Hoagland D., M&#xf8;ller R., Jordan T.X., Oishi K., Panis M., Sachs D., et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036&#x2013;1045.e9. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke J.M., St. Clair L.A., Perera R., Parker R. Rapid decay of host basal mRNAs during SARS-CoV-2 infection perturbs host antiviral mRNA biogenesis and export. bioRxiv. 2021 doi: 10.1101/2021.04.19.440452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.19.440452</ArticleId></ArticleIdList></Reference><Reference><Citation>Patra M.C., Choi S. Recent Progress in the Development of Toll-like Receptor (TLR) Antagonists. Expert Opin. Ther. Patents. 2016;26:719&#x2013;730. doi: 10.1080/13543776.2016.1185415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543776.2016.1185415</ArticleId><ArticleId IdType="pubmed">27136061</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki T., Kawai T. Toll-like Receptor Signaling Pathways. Front. Immunol. 2014;5:461. doi: 10.3389/fimmu.2014.00461.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00461</ArticleId><ArticleId IdType="pmc">PMC4174766</ArticleId><ArticleId IdType="pubmed">25309543</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G., Zhao Y. Toll-like receptors and immune regulation: Their direct and indirect modulation on regulatory CD4+ CD25+ T cells. Immunology. 2007;122:149&#x2013;156. doi: 10.1111/j.1365-2567.2007.02651.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2007.02651.x</ArticleId><ArticleId IdType="pmc">PMC2266004</ArticleId><ArticleId IdType="pubmed">17848162</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukkar M.B., Xie S., Khorasani N.M., Kon O.M., Stanbridge R., Issa R., Chung K.F. Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. J. Allergy Clin. Immunol. 2006;118:641&#x2013;648. doi: 10.1016/j.jaci.2006.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2006.05.013</ArticleId><ArticleId IdType="pubmed">16950283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesmeister M.J., Bothwell M.R., Misfeldt M.L. Toll-like receptor expression in the human nasopharyngeal tonsil (adenoid) and palantine tonsils: A preliminary report. Int. J. Pediatr. Otorhinolaryngol. 2006;70:987&#x2013;992. doi: 10.1016/j.ijporl.2005.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijporl.2005.10.009</ArticleId><ArticleId IdType="pubmed">16325925</ArticleId></ArticleIdList></Reference><Reference><Citation>Uehara A., Fujimoto Y., Fukase K., Takada H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol. Immunol. 2007;44:3100&#x2013;3111. doi: 10.1016/j.molimm.2007.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2007.02.007</ArticleId><ArticleId IdType="pubmed">17403538</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogefors J., Kvarnhammar A.M., Latif L., Petterson T., Uddman R., Cardell L.O. Retinoic acid-inducible gene 1-like receptors in the upper respiratory tract. Am. J. Rhinol. Allergy. 2011;25:E262&#x2013;E267. doi: 10.2500/ajra.2011.25.3712.</Citation><ArticleIdList><ArticleId IdType="doi">10.2500/ajra.2011.25.3712</ArticleId><ArticleId IdType="pubmed">22185736</ArticleId></ArticleIdList></Reference><Reference><Citation>Tengroth L., Millrud C.R., Kvarnhammar A.M., Geor&#xe9;n S.K., Latif L., Cardell L.-O. Functional effects of Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cells. PLoS ONE. 2014;9:e98239. doi: 10.1371/journal.pone.0098239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098239</ArticleId><ArticleId IdType="pmc">PMC4041746</ArticleId><ArticleId IdType="pubmed">24886842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.-T., Lidsky P.V., Xiao Y., Cheng R., Lee I.T., Nakayama T., Jiang S., He W., Demeter J., Knight M.G., et al. SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming. Cell. 2023;186:112&#x2013;130.e20. doi: 10.1016/j.cell.2022.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.11.030</ArticleId><ArticleId IdType="pmc">PMC9715480</ArticleId><ArticleId IdType="pubmed">36580912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst J., Prinz N., Lorenz M., Bauer S., Chapman J., Lackner K.J., von Landenberg P. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology. 2009;214:683&#x2013;691. doi: 10.1016/j.imbio.2008.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2008.12.003</ArticleId><ArticleId IdType="pubmed">19249118</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi M.O., Beltagy A., Garrafa E., Curreli D., Cecchini G., Bodio C., Grossi C., Blengino S., Tincani A., Franceschini F., et al. Anti-Phospholipid Antibodies in COVID-19 Are Different from Those Detectable in the Anti-Phospholipid Syndrome. Front. Immunol. 2020;11:584241. doi: 10.3389/fimmu.2020.584241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.584241</ArticleId><ArticleId IdType="pmc">PMC7593765</ArticleId><ArticleId IdType="pubmed">33178218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan T.A.J., O&#x2019;neill L.A.J. An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation. Cells. 2023;12:778. doi: 10.3390/cells12050778.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12050778</ArticleId><ArticleId IdType="pmc">PMC10001161</ArticleId><ArticleId IdType="pubmed">36899914</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith N., Poss&#xe9;m&#xe9; C., Bondet V., Sugrue J., Townsend L., Charbit B., Rouilly V., Saint-Andr&#xe9; V., Dott T., Pozo A.R., et al. Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity. Nat. Commun. 2022;13:7254. doi: 10.1038/s41467-022-34895-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34895-1</ArticleId><ArticleId IdType="pmc">PMC9700809</ArticleId><ArticleId IdType="pubmed">36434007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N., Ko R., Lee S.Y. Differential Expression Patterns of Toll-like Receptors in COVID-19 Patients. Front. Biosci. 2023;28:307. doi: 10.31083/j.fbl2811307.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.fbl2811307</ArticleId><ArticleId IdType="pubmed">38062845</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarember K.A., Godowski P.J. Tissue expression of human Tolllikereceptors and differential regulation of Toll-like receptormRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002;168:554&#x2013;561. doi: 10.4049/jimmunol.168.2.554.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.2.554</ArticleId><ArticleId IdType="pubmed">11777946</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;n M.P. TLR7 and TLR8 as targets in cancer therapy. Oncogene. 2008;27:190&#x2013;199. doi: 10.1038/sj.onc.1210913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1210913</ArticleId><ArticleId IdType="pubmed">18176600</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Yan Z., Wang J., Yao X. Toll-like receptors 7 and 8expression correlates with the expression of immune biomarkersand positively predicts the clinical outcome of patients withmelanoma. OncoTargets Ther. 2017;10:4339&#x2013;4346. doi: 10.2147/OTT.S136194.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S136194</ArticleId><ArticleId IdType="pmc">PMC5590684</ArticleId><ArticleId IdType="pubmed">28919783</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafilou M., Gamper F.G.J., Lepper P.M., Mouratis M.A., Schumann C., Harokopakis E., Schifferle R.E., Hajishengallis G., Triantafilou K. Lipopolysaccharides fromatherosclerosis-associated bacteria antagonize TLR4, induceformation of TLR2/1/CD36 complexes in lipid rafts and triggerTLR2-induced inflammatory responses in human vascularendothelial cells. Cell. Microbiol. 2007;9:2030&#x2013;2039. doi: 10.1111/j.1462-5822.2007.00935.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-5822.2007.00935.x</ArticleId><ArticleId IdType="pubmed">17419716</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreibelt G., Tel J., Sliepen K.H.E.W.J., Benitez-Ribas D., Figdor C.G., Adema G.J., de Vries I.J.M. Toll-like receptor expression andfunction in human dendritic cell subsets: Implications for dendriticcell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. 2010;59:1573&#x2013;1582. doi: 10.1007/s00262-010-0833-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-010-0833-1</ArticleId><ArticleId IdType="pmc">PMC11029854</ArticleId><ArticleId IdType="pubmed">20204387</ArticleId></ArticleIdList></Reference><Reference><Citation>Moen S.H., Ehrnstr&#xf6;m B., Kojen J.F., Yurchenko M., Beckwith K.S., Afset J.E., Dam&#xe5;s J.K., Hu Z., Yin H., Espevik T., et al. Human Toll-like Receptor 8 (TLR8) Is an ImportantSensor of Pyogenic Bacteria, and Is Attenuated by Cell SurfaceTLR Signaling. Front. Immunol. 2019;10:1209. doi: 10.3389/fimmu.2019.01209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01209</ArticleId><ArticleId IdType="pmc">PMC6554558</ArticleId><ArticleId IdType="pubmed">31214180</ArticleId></ArticleIdList></Reference><Reference><Citation>Greulich W., Wagner M., Gaidt M.M., Stafford C., Cheng Y., Linder A., Carell T., Hornung V. TLR8 Is a Sensor of RNase T2 Degradation Products. Cell. 2019;179:1264&#x2013;1275.e13. doi: 10.1016/j.cell.2019.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.11.001</ArticleId><ArticleId IdType="pmc">PMC7116005</ArticleId><ArticleId IdType="pubmed">31778653</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Wang J., Han Z., Zhang Y., Zhang H., Wang W., Chang J., Xia B., Fan S., Zhang D., et al. Structuralbasisforspecificrecognition of single-stranded RNA byToll-like receptor 13. Nat. Struct. Mol. Biol. 2015;22:782&#x2013;787. doi: 10.1038/nsmb.3080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.3080</ArticleId><ArticleId IdType="pubmed">26323037</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji H., Ohto U., Shibata T., Taoka M., Yamauchi Y., Isobe T., Miyake K., Shimizu T. Toll-like receptor 8 sensesdegradationproducts of single-stranded RNA. Nat. Struct. Mol. Biol. 2015;22:109&#x2013;115. doi: 10.1038/nsmb.2943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2943</ArticleId><ArticleId IdType="pubmed">25599397</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Ohto U., Shibata T., Krayukhina E., Taoka M., Yamauchi Y., Tanji H., Isobe T., Uchiyama S., Miyake K., et al. Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA. Immunity. 2016;45:737&#x2013;748. doi: 10.1016/j.immuni.2016.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.09.011</ArticleId><ArticleId IdType="pubmed">27742543</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Ohto U., Shibata T., Taoka M., Yamauchi Y., Sato R., Shukla N.M., David S.A., Isobe T., Miyake K., et al. StructuralAnalyses of Toll-like Receptor 7 RevealDetailed RNA SequenceSpecificity and RecognitionMechanism of AgonisticLigands. Cell Rep. 2018;25:3371&#x2013;3381.e3375. doi: 10.1016/j.celrep.2018.11.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.11.081</ArticleId><ArticleId IdType="pubmed">30566863</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind N.A., Rael V.E., Pestal K., Liu B., Barton G.M. Regulation of the nucleic acid-sensing Toll-like receptors. Nat. Rev. Immunol. 2022;22:224&#x2013;235. doi: 10.1038/s41577-021-00577-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00577-0</ArticleId><ArticleId IdType="pmc">PMC8283745</ArticleId><ArticleId IdType="pubmed">34272507</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino L., Fracella M., Frasca F., D&#x2019;auria A., Santinelli L., Maddaloni L., Bugani G., Bitossi C., Gentile M., Ceccarelli G., et al. Alterations in the Expression of IFN Lambda, IFN Gamma and Toll-like Receptors in Severe COVID-19 Patients. Microorganisms. 2023;11:689. doi: 10.3390/microorganisms11030689.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11030689</ArticleId><ArticleId IdType="pmc">PMC10058642</ArticleId><ArticleId IdType="pubmed">36985262</ArticleId></ArticleIdList></Reference><Reference><Citation>Menezes M.C.S., Veiga A.D.M., Martins de Lima T., Kunimi Kubo Ariga S., Vieira Barbeiro H., de Lucena Moreira C., Pinto A.A.S., Brandao R.A., Marchini J.F., Alencar J.C., et al. Lower peripheral blood Toll-like receptor 3 expression is associated with an unfavorable outcome in severe COVID-19 patients. Sci. Rep. 2021;11:15223. doi: 10.1038/s41598-021-94624-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94624-4</ArticleId><ArticleId IdType="pmc">PMC8316546</ArticleId><ArticleId IdType="pubmed">34315957</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali D.F.A., Gulen T.A., Ozmen E., Yuce Z.T., Yildiz O., Turunc T., Kayaba&#x15f; U. The Effect of Sex-Specific Genetic Factors on the Host Immune Response to COVID-19: A Pilot Study. Erciyes Med. J. 2022;44:594&#x2013;602.</Citation></Reference><Reference><Citation>van der Made C.I., Simons A., Schuurs-Hoeijmakers J., Heuvel G.v.D., Mantere T., Kersten S., van Deuren R.C., Steehouwer M., van Reijmersdal S.V., Jaeger M., et al. Presence of Genetic Variants Among Young Men with Severe COVID-19. JAMA. 2020;324:663&#x2013;673. doi: 10.1001/jama.2020.13719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.13719</ArticleId><ArticleId IdType="pmc">PMC7382021</ArticleId><ArticleId IdType="pubmed">32706371</ArticleId></ArticleIdList></Reference><Reference><Citation>du Bois H., Heim T.A., Rahman S.A., Yagnik B. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol. 2021;6:abl4348. doi: 10.1126/sciimmunol.abl4348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4348</ArticleId><ArticleId IdType="pmc">PMC8532080</ArticleId><ArticleId IdType="pubmed">34413140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Yang X.O. Dysregulation of Pulmonary Responses in Severe COVID-19. Viruses. 2021;13:957. doi: 10.3390/v13060957.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13060957</ArticleId><ArticleId IdType="pmc">PMC8224314</ArticleId><ArticleId IdType="pubmed">34064104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyagi S.C., Singh M. Multi-organ damage by COVID-19: Congestive (cardio-pulmonary) heart failure, and blood-heart barrier leakage. Mol. Cell. Biochem. 2021;476:1891&#x2013;1895. doi: 10.1007/s11010-021-04054-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-021-04054-z</ArticleId><ArticleId IdType="pmc">PMC7822399</ArticleId><ArticleId IdType="pubmed">33483858</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohmwald K., Diethelm-Varela B., Rodr&#xed;guez-Guilarte L., Rivera T., Riedel C.A., Gonz&#xe1;lez P.A., Kalergis A.M. Pathophysiological, immunological, and inflammatory features of long COVID. Front. Immunol. 2024;15:1341600. doi: 10.3389/fimmu.2024.1341600.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1341600</ArticleId><ArticleId IdType="pmc">PMC10932978</ArticleId><ArticleId IdType="pubmed">38482000</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.-W., Chen M.-F. Low compositions of human toll-like receptor 7/8-stimulating RNA motifs in theMERS-CoV, SARS-CoV and SARS-CoV-2 genomes imply a substantial ability to evade human innate immunity. PeerJ. 2021;9:e11008. doi: 10.7717/peerj.11008.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.11008</ArticleId><ArticleId IdType="pmc">PMC7912611</ArticleId><ArticleId IdType="pubmed">33665043</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerurkar L., McColl A., Graham G., Cavanagh J. The systemic response to topical aldara treatment is mediated through direct TLR7 stimulation as imiquimod enters the circulation. Sci. Rep. 2017;7:16570. doi: 10.1038/s41598-017-16707-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16707-5</ArticleId><ArticleId IdType="pmc">PMC5707416</ArticleId><ArticleId IdType="pubmed">29185473</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad K., Khatoon F., Rashid S., Ali N., AlAsmari A.F., Ahmed M.Z., Alqahtani A.S., Alqahtani M.S., Kumar V. Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective. Int. J. Biol. Macromol. 2020;163:1&#x2013;8. doi: 10.1016/j.ijbiomac.2020.06.228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.06.228</ArticleId><ArticleId IdType="pmc">PMC7319641</ArticleId><ArticleId IdType="pubmed">32599245</ArticleId></ArticleIdList></Reference><Reference><Citation>Park A., Iwasaki A. Type I and Type III Interferons&#x2013;Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host Microbe. 2020;27:870&#x2013;878. doi: 10.1016/j.chom.2020.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7255347</ArticleId><ArticleId IdType="pubmed">32464097</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto-Fontarigo J.J., Tillgren S., Cerps S., Sverrild A., Hvidtfeldt M., Ramu S., Menzel M., Sander A.F., Porsbjerg C., Uller L. Imiquimod Boosts Interferon Response, and Decreases ACE2 and Proinflammatory Response of Human Bronchial Epithelium in Asthma. Front. Immunol. 2021;12:743890. doi: 10.3389/fimmu.2021.743890.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.743890</ArticleId><ArticleId IdType="pmc">PMC8688760</ArticleId><ArticleId IdType="pubmed">34950134</ArticleId></ArticleIdList></Reference><Reference><Citation>Garland S.M., Waddell R., Mindel A., Denham I.M., McCloskey J.C. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int. J. STD AIDS. 2006;17:448&#x2013;452. doi: 10.1258/095646206777689161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/095646206777689161</ArticleId><ArticleId IdType="pubmed">16820073</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z.-M., Yang M.-H., Yu K., Lian Z.-X., Deng S.-L. Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments. Front. Pharmacol. 2022;13:989664. doi: 10.3389/fphar.2022.989664.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.989664</ArticleId><ArticleId IdType="pmc">PMC9518217</ArticleId><ArticleId IdType="pubmed">36188605</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C.-F., Yen C.-L., Fu Y.-C., Cheng C.-M., Shen T.-C., Chang P.-D., Cheng K.-H., Liu C.-C., Chang Y.-T., Chen P.-L., et al. Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production after ChAdOx1nCoV-19 Vaccination. Front. Immunol. 2022;13:807454. doi: 10.3389/fimmu.2022.807454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.807454</ArticleId><ArticleId IdType="pmc">PMC8822242</ArticleId><ArticleId IdType="pubmed">35145520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley S.F., Wei J., O&#x2019;donnell D., E Stoesser N., Matthews P.C., Howarth A., Hatch S.B., Marsden B.D., Cox S., James T., et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin. Infect. Dis. 2021;73:e699&#x2013;e709. doi: 10.1093/cid/ciab004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab004</ArticleId><ArticleId IdType="pmc">PMC7929225</ArticleId><ArticleId IdType="pubmed">33400782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Zhu J., Liu Z., Li C., Guo Y., Wang Y., Chen K. Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses. Front. Immunol. 2022;13:864278. doi: 10.3389/fimmu.2022.864278.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.864278</ArticleId><ArticleId IdType="pmc">PMC9389018</ArticleId><ArticleId IdType="pubmed">35990623</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkhipova-Jenkins I., Helfand M., Armstrong C., Gean E., Anderson J., Paynter R.A., Mackey K. Antibody response after SARS-Cov-2 infection and implications for immunity: A rapid living review. Ann. Intern. Med. 2021;174:811&#x2013;821. doi: 10.7326/M20-7547.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-7547</ArticleId><ArticleId IdType="pmc">PMC8025942</ArticleId><ArticleId IdType="pubmed">33721517</ArticleId></ArticleIdList></Reference><Reference><Citation>Markewitz R.D.H., Juhl D., Pauli D., G&#xf6;rg S., Junker R., Rupp J., Engel S., Steinhagen K., Herbst V., Zapf D., et al. Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2. Vaccines. 2022;10:649. doi: 10.3390/vaccines10050649.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050649</ArticleId><ArticleId IdType="pmc">PMC9145236</ArticleId><ArticleId IdType="pubmed">35632405</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., St Denis K.J., Hoelzemer A., Lam E.C., Nitido A.D., Sheehan M.L., Berrios C., Ofoman O., Chang C.C., Hauser B.M., et al. mRNA-Based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185:457&#x2013;466.e4. doi: 10.1016/j.cell.2021.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.033</ArticleId><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Qin C., Liu M., Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis. Infect. Dis. Poverty. 2021;10:132. doi: 10.1186/s40249-021-00915-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-021-00915-3</ArticleId><ArticleId IdType="pmc">PMC8590867</ArticleId><ArticleId IdType="pubmed">34776011</ArticleId></ArticleIdList></Reference><Reference><Citation>Garland S.M. Imiquimod. Curr. Opin. Infect. Dis. 2003;16:85&#x2013;89. doi: 10.1097/00001432-200304000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001432-200304000-00004</ArticleId><ArticleId IdType="pubmed">12734440</ArticleId></ArticleIdList></Reference><Reference><Citation>Patinote C., Karroum N.B., Moarbess G., Cirnat N., Kassab I., Bonnet P.-A., Deleuze-Masqu&#xe9;fa C. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur. J. Med. Chem. 2020;193:112238. doi: 10.1016/j.ejmech.2020.112238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2020.112238</ArticleId><ArticleId IdType="pmc">PMC7173040</ArticleId><ArticleId IdType="pubmed">32203790</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna V., Kim H., Zhang W., Larson P., Shah M., Griffith T.S., Ferguson D., Panyam J. Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC) Sci. Rep. 2021;11:3346. doi: 10.1038/s41598-021-83005-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-83005-6</ArticleId><ArticleId IdType="pmc">PMC7870826</ArticleId><ArticleId IdType="pubmed">33558639</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammerl V., Parlar B., Navarini A., Gantenbein L., V&#xe4;th H., Mueller S.M. Mucosal side effects in patients treated with topical imiquimod&#x2014;A scoping review of the literature. Dermatol. Ther. 2020;34:e14355. doi: 10.1111/dth.14355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.14355</ArticleId><ArticleId IdType="pubmed">32990395</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagchandani S., Johnson J.A., Irvine D.J. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. Adv. Drug Deliv. Rev. 2021;175:113803. doi: 10.1016/j.addr.2021.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2021.05.013</ArticleId><ArticleId IdType="pmc">PMC9003539</ArticleId><ArticleId IdType="pubmed">34058283</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner R.B. Imiquimod as an immune response modulator in infectious conditions. J. Postgrad. Med. 2002;112((Suppl. S6)):8&#x2013;16. doi: 10.3810/pgm.2002.12.suppl23.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3810/pgm.2002.12.suppl23.120</ArticleId><ArticleId IdType="pubmed">19667608</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson S.J., Lindh J.M., Riter T.R., Gleason R.M., Rogers L.M., E Fuller A., Oesterich J.L., Gorden K.B., Qiu X., McKane S.W., et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol. 2002;218:74&#x2013;86. doi: 10.1016/S0008-8749(02)00517-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0008-8749(02)00517-8</ArticleId><ArticleId IdType="pubmed">12470615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chosidow O., Dummer R. Imiquimod: Mode of action and therapeutic potential. Acta Derm. Venereol. 2003;83:8&#x2013;11. doi: 10.1080/00015555-832143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00015555-832143</ArticleId><ArticleId IdType="pubmed">14606276</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy E.J., Parker A.E., O&#x2019;Neill L.A.J. Targeting Toll-like receptors: Emerging therapeutics? Nat. Rev. Drug Discov. 2010;9:293&#x2013;307. doi: 10.1038/nrd3203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3203</ArticleId><ArticleId IdType="pubmed">20380038</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.A., Brown M.D. Imiquimod for the treatment of skin cancer. Dermatol. Clin. 2005;23:151&#x2013;164. doi: 10.1016/j.det.2004.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.det.2004.08.007</ArticleId><ArticleId IdType="pubmed">15620626</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty A., Geisse J.K. Medical therapies for non-melanoma skin cancer. Clin. Dermatol. 2004;22:183&#x2013;188. doi: 10.1016/j.clindermatol.2003.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clindermatol.2003.12.005</ArticleId><ArticleId IdType="pubmed">15262303</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison L.I., Skinner S.L., Marbury T.C., Owens M.L., Kurup S., McKane S., Greene R.J. Pharmacokinetics andsafety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch. Dermatol. Res. 2004;296:6&#x2013;11. doi: 10.1007/s00403-004-0465-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00403-004-0465-4</ArticleId><ArticleId IdType="pubmed">15083310</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J., Uerlich M., Haller O., Bieber T., Tueting T. Enhanced type I interferon signaling and recruitment ofchemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J. Cutan. Pathol. 2005;32:257&#x2013;262. doi: 10.1111/j.0303-6987.2005.00297.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0303-6987.2005.00297.x</ArticleId><ArticleId IdType="pubmed">15769273</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulka M., Metcalfe D. TLR3 activation inhibits human mast cell attachment to fibronectin and vitronectin. Mol. Immunol. 2005;43:1579&#x2013;1586. doi: 10.1016/j.molimm.2005.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2005.09.019</ArticleId><ArticleId IdType="pubmed">16280166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;n M.P., Sch&#xf6;n M. Immune modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod. Apoptosis. 2004;9:291&#x2013;298. doi: 10.1023/B:APPT.0000025805.55340.c3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:APPT.0000025805.55340.c3</ArticleId><ArticleId IdType="pubmed">15258460</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandig H., Bulfone-Paus S. TLR signaling in mast cells: Common and unique features. Front. Immunol. 2012;3:185. doi: 10.3389/fimmu.2012.00185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00185</ArticleId><ArticleId IdType="pmc">PMC3389341</ArticleId><ArticleId IdType="pubmed">22783258</ArticleId></ArticleIdList></Reference><Reference><Citation>Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529&#x2013;1531. doi: 10.1126/science.1093616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1093616</ArticleId><ArticleId IdType="pubmed">14976261</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarf&#xec; F., Patrizi A., Veronesi G., Lambertini M., Tartari F., Mussi M., Melotti B., Dika E. The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature. Dermatol. Ther. 2020;33:e14165. doi: 10.1111/dth.14165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.14165</ArticleId><ArticleId IdType="pubmed">32772481</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantisani C., Lazic T., Richetta A.G., Clerico R., Mattozzi C., Calvieri S. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat. Inflamm. Allergy Drug Discov. 2012;6:65&#x2013;69. doi: 10.2174/187221312798889301.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187221312798889301</ArticleId><ArticleId IdType="pubmed">22185454</ArticleId></ArticleIdList></Reference><Reference><Citation>Calenic B., Greabu M., Caruntu C., Tanase C., Battino M. Oral keratinocyte stem/progenitor cells: Specific markers, molecular signaling pathways and potential uses. Periodontology 2000. 2015;69:68&#x2013;82. doi: 10.1111/prd.12097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/prd.12097</ArticleId><ArticleId IdType="pubmed">26252402</ArticleId></ArticleIdList></Reference><Reference><Citation>Drobits B., Holcmann M., Amberg N., Swiecki M., Grundtner R., Hammer M., Colonna M., Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Investig. 2012;122:575&#x2013;585. doi: 10.1172/JCI61034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI61034</ArticleId><ArticleId IdType="pmc">PMC3266798</ArticleId><ArticleId IdType="pubmed">22251703</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;n M. Imiquimod: Mode of action. Br. J. Dermatol. 2007;157:8&#x2013;13. doi: 10.1111/j.1365-2133.2007.08265.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2007.08265.x</ArticleId><ArticleId IdType="pubmed">18067624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002;3:196&#x2013;200. doi: 10.1038/ni758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni758</ArticleId><ArticleId IdType="pubmed">11812998</ArticleId></ArticleIdList></Reference><Reference><Citation>Dummer R., Urosevic M., Kempf W., Hoek K., Hafner J., Burg G. Imiquimod in basal cell carcinoma: How does it work? Br. J. Dermatol. 2003;149:57&#x2013;58. doi: 10.1046/j.0366-077X.2003.05630.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0366-077X.2003.05630.x</ArticleId><ArticleId IdType="pubmed">14616353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupu M., Caruntu C., Ghita M.A., Voiculescu V., Voiculescu S., Rosca A.E., Caruntu A., Moraru L., Popa I.M., Calenic B., et al. Gene expression and proteome analysis as sources of biomarkers in basal cell carcinoma. Dis. Markers. 2016;2016:9831237. doi: 10.1155/2016/9831237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/9831237</ArticleId><ArticleId IdType="pmc">PMC4992754</ArticleId><ArticleId IdType="pubmed">27578920</ArticleId></ArticleIdList></Reference><Reference><Citation>Batinac T., Zamolo G., Jonji&#x107; N., Gruber F., Petrove&#x10d;ki M. p53 protein expression and cell proliferation in non-neoplastic and neoplastic proliferative skin diseases. Tumori J. 2004;90:120&#x2013;127. doi: 10.1177/030089160409000124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/030089160409000124</ArticleId><ArticleId IdType="pubmed">15143984</ArticleId></ArticleIdList></Reference><Reference><Citation>Smole&#x144;ski M., Karolewicz B., Go&#x142;kowska A.M., Nartowski K.P., Ma&#x142;olepsza-Jarmo&#x142;owska K. Emulsion-Based Multicompartment Vaginal Drug Carriers: From Nanoemulsions to Nanoemulgels. Int. J. Mol. Sci. 2021;22:6455. doi: 10.3390/ijms22126455.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22126455</ArticleId><ArticleId IdType="pmc">PMC8233730</ArticleId><ArticleId IdType="pubmed">34208652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrall L., Lin K.Y., Roden R.B., Hung C.-F., Wu T.-C. Cervical Cancer Immunotherapy: Facts and Hopes. Clin. Cancer Res. 2021;27:4953&#x2013;4973. doi: 10.1158/1078-0432.CCR-20-2833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-2833</ArticleId><ArticleId IdType="pmc">PMC8448896</ArticleId><ArticleId IdType="pubmed">33888488</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank L.A., Gazzi R.P., Mello P.A., Chaves P., Pe&#xf1;a F., Beck R.C.R., Buffon A., Pohlmann A.R., Guterres S.S. Anti-HPV Nanoemulsified-Imiquimod: A New and Potent Formulation to Treat Cervical Cancer. AAPS Pharmscitech. 2020;21:54. doi: 10.1208/s12249-019-1558-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-019-1558-x</ArticleId><ArticleId IdType="pubmed">31907712</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwar M.A., Shah M., Kim J., Choi S. Recent clinical trends in Toll-like receptor targeting therapeutics. Med. Res. Rev. 2018;39:1053&#x2013;1090. doi: 10.1002/med.21553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21553</ArticleId><ArticleId IdType="pmc">PMC6587958</ArticleId><ArticleId IdType="pubmed">30450666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalluri R., LeBleu V.S. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977. doi: 10.1126/science.aau6977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aau6977</ArticleId><ArticleId IdType="pmc">PMC7717626</ArticleId><ArticleId IdType="pubmed">32029601</ArticleId></ArticleIdList></Reference><Reference><Citation>Caimi A.T., Altube M.J., de Farias M.A., Portugal R.V., Perez A.P., Romero E.L., Morilla M.J. Novel imiquimod nanovesicles for topical vaccination. Colloids Surf. B Biointerfaces. 2018;174:536&#x2013;543. doi: 10.1016/j.colsurfb.2018.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2018.11.031</ArticleId><ArticleId IdType="pubmed">30500742</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., Lipford G., Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 2002;3:499. doi: 10.1038/ni0602-499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni0602-499</ArticleId><ArticleId IdType="pubmed">12032557</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorden K.B., Gorski K.S., Gibson S.J., Kedl R.M., Kieper W.C., Qiu X., Tomai M.A., Alkan S.S., Vasilakos J.P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 2005;174:1259&#x2013;1268. doi: 10.4049/jimmunol.174.3.1259.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.3.1259</ArticleId><ArticleId IdType="pubmed">15661881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieffer M.E., Patel A.M., Hollingsworth S.A., Seganish W.M. Small molecule agonists of toll-like receptors 7 and 8: A patent review 2014&#x2013;2020. Expert OpinTher Pat. 2020;30:825&#x2013;845. doi: 10.1080/13543776.2020.1825687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543776.2020.1825687</ArticleId><ArticleId IdType="pubmed">33052748</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M., Larson P.G., Brown L., Schultz J.R., Kucaba T.A., Griffith T.S., Ferguson D.M. Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs. Bioorganic Med. Chem. Lett. 2022;59:128548. doi: 10.1016/j.bmcl.2022.128548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2022.128548</ArticleId><ArticleId IdType="pubmed">35051578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota Y., Nagai Y., Hirose Y., Hori S., Koga-Yamakawa E., Eguchi K., Sumida K., Murata M., Umehara H., Yamamoto S. DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects. Front. Immunol. 2023;14:1055671. doi: 10.3389/fimmu.2023.1055671.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1055671</ArticleId><ArticleId IdType="pmc">PMC9922899</ArticleId><ArticleId IdType="pubmed">36793737</ArticleId></ArticleIdList></Reference><Reference><Citation>Abiri A., Rezaei M., Zeighami M.H., Vaezpour Y., Dehghan L., Khorram Ghahfarokhi M. Discovery of new TLR7 agonists by a combination of statistical learning-based QSAR, virtual screening, and molecular dynamics. Informatics Med. Unlocked. 2021;27:100787. doi: 10.1016/j.imu.2021.100787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imu.2021.100787</ArticleId><ArticleId IdType="pmc">PMC8591993</ArticleId><ArticleId IdType="pubmed">34805481</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldara&#xae; (Imiquimod) Cream, 5% [Package Insert]. United States Food and Drug Administration.  [(accessed on 10 July 2024)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020723s022lbl.pdf.</Citation></Reference><Reference><Citation>Aldara 5% Cream. European Medicines Agency: European Public Assessment Report&#x2013;Product Information. Revised May 6, 2021.  [(accessed on 10 July 2024)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/</Citation></Reference><Reference><Citation>Bong A.B., Bonnekoh B., Franke I., Sch&#xf6;n M.P., Ulrich J., Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 2002;205:135&#x2013;138. doi: 10.1159/000063904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000063904</ArticleId><ArticleId IdType="pubmed">12218228</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinfeld N., Lehman D.S. An evidence-based review of medical and surgical treatments of genital warts. Dermatol. Online J. 2006;12:5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16638419</ArticleId></ArticleIdList></Reference><Reference><Citation>Voiculescu V.M., Lisievici C.V., Lupu M., Vajaitu C., Draghici C.C., Popa A.V., Solomon I., Sebe T.I., Constantin M.M., Caruntu C. Mediators of inflammation in topical therapy of skin cancers. Mediat. Inflamm. 2019;2019:8369690. doi: 10.1155/2019/8369690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/8369690</ArticleId><ArticleId IdType="pmc">PMC6350587</ArticleId><ArticleId IdType="pubmed">30766448</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez M.I., Sanchez-Carpintero I., North P.E., Mihm M.C., Jr. Infantile hemangioma: Clinical resolution with 5% imiquimod cream. Arch. Dermatol. 2002;138:881&#x2013;884. doi: 10.1001/archderm.138.7.881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archderm.138.7.881</ArticleId><ArticleId IdType="pubmed">12071813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho N.T., Lansang P., Pope E. Topical imiquimod in the treatment of infantile hemangiomas: A retrospective study. J. Am. Acad. Dermatol. 2007;56:63&#x2013;68. doi: 10.1016/j.jaad.2006.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2006.06.011</ArticleId><ArticleId IdType="pubmed">17190622</ArticleId></ArticleIdList></Reference><Reference><Citation>McCuaig C.C., Dubois J., Powell J., Belleville C., David M., Rousseau &#xc9;., Gendron R., Jafarian F., Auger I. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr. Dermatol. 2009;26:203&#x2013;212. doi: 10.1111/j.1525-1470.2008.00857.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1470.2008.00857.x</ArticleId><ArticleId IdType="pubmed">19419474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez S., del Boz J., Vera &#xc1;., Sanz A., Crespo V. Spindle-cell carcinoma in situ treated with 5% imiquimod. Actas Dermo-Sifiliogr. 2006;97:267&#x2013;270. doi: 10.1016/S0001-7310(06)73397-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0001-7310(06)73397-X</ArticleId><ArticleId IdType="pubmed">16801022</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Moyano E., Crespo-Erchiga A., Casa&#xf1;o A.V., Trelles A.S. Pityriasis rubra pilaris with focal acantholytic dyskeratosis during treatment with imiquimod 5% cream. Actas Dermo-Sifiliogr. 2010;101:898&#x2013;900. doi: 10.1016/j.ad.2010.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ad.2010.03.024</ArticleId><ArticleId IdType="pubmed">21159271</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor L.A., Gormley R., Kovarik C. Leishmania tropica: Combined debulking and imiquimod for the treatment of nonresponsive cutaneous leishmaniasis. J. Am. Acad. Dermatol. 2017;76:e13&#x2013;e14. doi: 10.1016/j.jaad.2016.08.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2016.08.040</ArticleId><ArticleId IdType="pubmed">27986151</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . Morbidity and Mortality Weekly Report. Dept. of Health and Human Services; Atlanta, GA, USA: 2002. Sexually Transmitted Diseases, Treatment Guidelines.</Citation></Reference><Reference><Citation>Edwards L., Ferenczy A., Eron L., Baker D., Owens M.L., Fox T.L., Hougham A.J., Schmitt K.A. Self-administered topical 5 % imiquimod cream for external anogenital warts. HPV Study Group. Human Papillomavirus. Arch. Dermatol. 1998;134:25&#x2013;30. doi: 10.1001/archderm.134.1.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archderm.134.1.25</ArticleId><ArticleId IdType="pubmed">9449906</ArticleId></ArticleIdList></Reference><Reference><Citation>Polterauer S., Reich O., Widschwendter A., Hadjari L., Bogner G., Reinthaller A., Joura E., Trutnovsky G., Ciresa-Koenig A., Ganhoer-Schimboeck J., et al. Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial. Gynecol. Oncol. 2022;165:23&#x2013;29. doi: 10.1016/j.ygyno.2022.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2022.01.033</ArticleId><ArticleId IdType="pubmed">35177279</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., Shetty A., Delanerolle G., Zeng Y., Zhang Y., Raymont V., Rathod S., Halabi S., Elliot K., Shi J.Q., et al. A systematic review and meta-analysis of long COVID symptoms. Syst. Rev. 2023;12:88. doi: 10.1186/s13643-023-02250-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-023-02250-0</ArticleId><ArticleId IdType="pmc">PMC10220332</ArticleId><ArticleId IdType="pubmed">37245047</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C., Liu Z., Li S., Wang Y., Liu G. Impact of Long COVID on Health-Related Quality of Life Among Patients After Acute COVID-19 Infection: A Cross-Sectional Study. Inq. J. Health Care Organ. Provis. Financ. 2024;61:469580241246461. doi: 10.1177/00469580241246461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00469580241246461</ArticleId><ArticleId IdType="pmc">PMC11036910</ArticleId><ArticleId IdType="pubmed">38646896</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Xu Z.-Z., Park C.-K., Berta T., Ji R.-R. Toll-like receptor 7 mediates pruritus. Nat. Neurosci. 2010;13:1460&#x2013;1462. doi: 10.1038/nn.2683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2683</ArticleId><ArticleId IdType="pmc">PMC2991508</ArticleId><ArticleId IdType="pubmed">21037581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar B., Narang T. Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation. Sex. Transm. Infect. 2011;87:432. doi: 10.1136/sextrans-2011-050025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/sextrans-2011-050025</ArticleId><ArticleId IdType="pubmed">21606474</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Fits L., Mourits S., Voerman J.S.A., Kant M., Boon L., Laman J.D., Cornelissen F., Mus A.-M., Florencia E., Prens E.P., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 2009;182:5836&#x2013;5845. doi: 10.4049/jimmunol.0802999.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0802999</ArticleId><ArticleId IdType="pubmed">19380832</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Xie Y., Wang L. Rare Cutaneous Side Effects of Imiquimod: A Review on Its Mechanisms, Diagnosis, and Management. Dermatol. Ther. 2023;13:1909&#x2013;1934. doi: 10.1007/s13555-023-00978-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13555-023-00978-0</ArticleId><ArticleId IdType="pmc">PMC10442311</ArticleId><ArticleId IdType="pubmed">37528289</ArticleId></ArticleIdList></Reference><Reference><Citation>Flutter B., Nestle F.O. TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis. Eur. J. Immunol. 2013;43:3138&#x2013;3146. doi: 10.1002/eji.201343801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201343801</ArticleId><ArticleId IdType="pubmed">24254490</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel U., Mark N., Machler B., Levine V. Imiquimod 5% cream induced psoriasis: A case report, summary of the literature and mechanism. Br. J. Dermatol. 2011;164:670&#x2013;672. doi: 10.1111/j.1365-2133.2010.10124.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2010.10124.x</ArticleId><ArticleId IdType="pubmed">21062268</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia H.-X., He Y.-L. Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: A meta-analysis of randomized controlled trial. J. Dermatol. Treat. 2020;31:831&#x2013;838. doi: 10.1080/09546634.2019.1638883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09546634.2019.1638883</ArticleId><ArticleId IdType="pubmed">31294669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni&#x21b;escu D.A.-M., Mu&#x219;etescu A., Ni&#x21b;escu M., Costescu M., Coman O.-A. Experimental research in topical psoriasis therapy (Review) Exp. Ther. Med. 2021;22:971. doi: 10.3892/etm.2021.10403.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10403</ArticleId><ArticleId IdType="pmc">PMC8290406</ArticleId><ArticleId IdType="pubmed">34335913</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinter H., Iversen L., Steiniche T., Kragballe K., Johansen C. Aldara&#xae;-induced skin inflammation: Studies of patients with psoriasis. Br. J. Dermatol. 2014;172:345&#x2013;353. doi: 10.1111/bjd.13236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.13236</ArticleId><ArticleId IdType="pubmed">24980460</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto N.M.R., Wyss M., Dummer R. mRNA COVID 19 vaccine-induced recall dermatitis after topical imiquimod. J. Dtsch. Dermatol. Ges. 2023;21:659&#x2013;660. doi: 10.1111/ddg.15036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ddg.15036</ArticleId><ArticleId IdType="pubmed">37066611</ArticleId></ArticleIdList></Reference><Reference><Citation>Redwan E.M. COVID-19 pandemic and vaccination build herd immunity. Eur. Rev. Med. Pharmacol. Sci. 2021;25:577&#x2013;579. doi: 10.26355/eurrev_202101_24613.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202101_24613</ArticleId><ArticleId IdType="pubmed">33577008</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco-Garc&#xed;a U., Seraf&#xed;n-L&#xf3;pez J. Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity. Vaccines. 2023;11:655. doi: 10.3390/vaccines11030655.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030655</ArticleId><ArticleId IdType="pmc">PMC10055900</ArticleId><ArticleId IdType="pubmed">36992239</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., To K.K.W., Zhang A.J.X., Lee A.C.Y., Zhu H., Mak W.W.N., Hung I.F.N., Yuen K.-Y. Co-stimulation with TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production. Front. Immunol. 2018;9:2370. doi: 10.3389/fimmu.2018.02370.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02370</ArticleId><ArticleId IdType="pmc">PMC6194170</ArticleId><ArticleId IdType="pubmed">30369932</ArticleId></ArticleIdList></Reference><Reference><Citation>To E.E., Erlich J., Liong F., Luong R., Liong S., Bozinovski S., Seow H.J., O&#x2019;leary J.J., Brooks D.A., Vlahos R., et al. Intranasal and epicutaneous administration of Toll-like receptor 7 (TLR7) agonists provides protection against influenza A virus-induced morbidity in mice. Sci. Rep. 2019;9:2366. doi: 10.1038/s41598-019-38864-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-38864-5</ArticleId><ArticleId IdType="pmc">PMC6382773</ArticleId><ArticleId IdType="pubmed">30787331</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung I.F.-N., Zhang A.J., To K.K.-W., Chan J.F.-W., Li P., Wong T.-L., Zhang R., Chan T.-C., Chan B.C.-Y., Wai H.H., et al. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: A single-centre, doubleblind, randomised, controlled phase 2b/3 trial. Lancet Infect. Dis. 2015;16:209&#x2013;218. doi: 10.1016/S1473-3099(15)00354-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00354-0</ArticleId><ArticleId IdType="pubmed">26559482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R.Y., Zhou S.H., He C.B., Wang J., Wen Y., Feng R.R., Yin X.G., Yang G.F., Guo J. Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern. ACS Infect. Dis. 2022;8:1367&#x2013;1375. doi: 10.1021/acsinfecdis.2c00259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.2c00259</ArticleId><ArticleId IdType="pubmed">35748575</ArticleId></ArticleIdList></Reference><Reference><Citation>Jangra S., De Vrieze J., Choi A., Rathnasinghe R., Laghlali G., Uvyn A., Van Herck S., Nuhn L., Deswarte K., Zhong Z., et al. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine. Angew. Chem. Int. Ed. 2021;60:9467&#x2013;9473. doi: 10.1002/anie.202015362. Erratum in Angew. Chem. Int. Ed. 2021, 60, 16741&#x2013;16742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202015362</ArticleId><ArticleId IdType="pmc">PMC8014308</ArticleId><ArticleId IdType="pubmed">33464672</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S., Berth-Jones J. Porokeratosis of Mibelli: Successful treatment with 5% imiquimod cream. Br. J. Dermatol. 2002;146:338&#x2013;339. doi: 10.1046/j.1365-2133.2002.4653_8.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2133.2002.4653_8.x</ArticleId><ArticleId IdType="pubmed">11903259</ArticleId></ArticleIdList></Reference><Reference><Citation>Herron M.D., Bowen A.R., Krueger G.G. Seborrheic keratoses: A study comparing the standard cryosurgery with topical calcipotriene, topical azarotene, and topical imiquimod. Int. J. Dermatol. 2004;43:300&#x2013;302. doi: 10.1111/j.1365-4632.2004.02282.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-4632.2004.02282.x</ArticleId><ArticleId IdType="pubmed">15090020</ArticleId></ArticleIdList></Reference><Reference><Citation>Carre D., Dompmartin A., Verneuil L., Verdon R., Comoz F., Le Brun E., Freymuth F., Leroy D. Epidermodysplasia verruciformis in a patient with HIV infection: No response to highly active antiretroviral therapy. Int. J. Dermatol. 2003;42:296&#x2013;300. doi: 10.1046/j.1365-4362.2003.01707_2.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-4362.2003.01707_2.x</ArticleId><ArticleId IdType="pubmed">12694498</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro A., Zhao J., Wu L., Carru C., Biagi E., Franceschi C. Microbiomes other than the gut: Inflammaging and age-related diseases. Semin. Immunopathol. 2020;42:589&#x2013;605. doi: 10.1007/s00281-020-00814-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-020-00814-z</ArticleId><ArticleId IdType="pmc">PMC7666274</ArticleId><ArticleId IdType="pubmed">32997224</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman L.S., Osborne L.C. A gut-centric view of aging: Do intestinal epithelial cells contribute to age-associated microbiota changes, inflammaging, and immunosenescence? Aging Cell. 2022;21:e13700. doi: 10.1111/acel.13700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13700</ArticleId><ArticleId IdType="pmc">PMC9470900</ArticleId><ArticleId IdType="pubmed">36000805</ArticleId></ArticleIdList></Reference><Reference><Citation>Moos S., Mohebiany A.N., Waisman A., Kurschus F.C. Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. J. Investig. Dermatol. 2019;139:1110&#x2013;1117. doi: 10.1016/j.jid.2019.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2019.01.006</ArticleId><ArticleId IdType="pubmed">30684554</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Liu W., Gao S., Mao Y., Xin Y. Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist. BMC Immunol. 2021;22:11. doi: 10.1186/s12865-021-00401-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-021-00401-3</ArticleId><ArticleId IdType="pmc">PMC7844923</ArticleId><ArticleId IdType="pubmed">33509093</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B.-Y., Cheng Y.-G., Liu Y., Liu Y., Tan J.-Y., Guan W., Guo S., Kuang H.-X. Datura metel L. Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis and Inhibits Inflammatory Cytokines Production through TLR7/8-MyD88-NF-&#x3ba;B-NLRP3 Inflammasome Pathway. Molecules. 2019;24:2157. doi: 10.3390/molecules24112157.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24112157</ArticleId><ArticleId IdType="pmc">PMC6600670</ArticleId><ArticleId IdType="pubmed">31181689</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Liu Z., Lin Z., Cun D., Tong H.H., Yan R., Wang R., Zheng Y. Comparison of normal versus imiquimod-induced psoriatic skin in mice for penetration of drugs and nanoparticles. Int. J. Nanomed. 2018;13:5625&#x2013;5635. doi: 10.2147/IJN.S170832.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S170832</ArticleId><ArticleId IdType="pmc">PMC6154705</ArticleId><ArticleId IdType="pubmed">30271151</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg M., He S., Harwood C., Arron S., Demehri S., Green A., Asgari M., NCI Keratinocyte Carcinoma Consortium Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients. Br. J. Dermatol. 2017;177:1225&#x2013;1233. doi: 10.1111/bjd.15950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.15950</ArticleId><ArticleId IdType="pmc">PMC5711582</ArticleId><ArticleId IdType="pubmed">29086412</ArticleId></ArticleIdList></Reference><Reference><Citation>Trakatelli M., Katsanos G., Ulrich C., Kalabalikis D., Sotiriadis D., Stockfleth E. Efforts to counteract locally the effects of systemic immunosupression: A review on the use of imiquimod, a topical immunostimulator in organ transplant recipients. Int. J. Immunopathol. Pharmacol. 2010;23:387&#x2013;396. doi: 10.1177/039463201002300201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/039463201002300201</ArticleId><ArticleId IdType="pubmed">20646334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>